Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review
Open Access
Abstract
Treatment-resistant schizophrenia (TRS) is often associated with severe burden of disease, poor quality of life and functional impairment. Clozapine is the gold standard for the treatment of TRS, although it is also known to cause significant side effects in some patients. In view of the burgeoning interest in the role of genetic factors in precision psychiatry, we conducted a scoping review to narratively summarize the current genetic factors associated with TRS, clozapine resistance and side effects to clozapine treatment. We searched PubMed from inception to December 2022 and included 104 relevant studies in this review. Extant evidence comprised associations between TRS and clozapine resistance with genetic factors related to mainly dopaminergic and serotoninergic neurotransmitter systems, specifically, TRS and rs4680, rs4818 within COMT, and rs1799978 within DRD2; clozapine resistance and DRD3 polymorphisms, CYP1A2 polymorphisms; weight gain with LEP and SNAP-25 genes; and agranulocytosis risk with HLA-related polymorphisms. Future studies, including replication in larger multi-site samples, are still needed to elucidate putative risk genes and the interactions between different genes and their correlations with relevant clinical factors such as psychopathology, psychosocial functioning, cognition and progressive changes with treatment over time in TRS and clozapine resistance.Keywords
This publication has 185 references indexed in Scilit:
- Abnormal synaptic pruning in schizophrenia: Urban myth or reality?Journal of Psychiatry and Neuroscience, 2012
- Serine proteases, serine protease inhibitors, and protease-activated receptors: Roles in synaptic function and behaviorBrain Research, 2011
- Association between type‐three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophreniaHuman Psychopharmacology: Clinical and Experimental, 2011
- Mouse neurexin-1α deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairmentsProceedings of the National Academy of Sciences, 2009
- The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variationPharmacogenetics and Genomics, 2009
- Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance ProteinBasic & Clinical Pharmacology & Toxicology, 2008
- Association study of GSK3 gene polymorphisms with schizophrenia and clozapine responsePsychopharmacology, 2008
- Neuregulin 1 in neural development, synaptic plasticity and schizophreniaNature Reviews Neuroscience, 2008
- AKT1 Is Associated with Schizophrenia Across Multiple Symptom Dimensions in the Irish Study of High Density Schizophrenia FamiliesBiological Psychiatry, 2008
- Outpatient Antipsychotic Treatment and Inpatient Costs of SchizophreniaSchizophrenia Bulletin, 2007